—
Summary‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016’, provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/685904-human-papillomavirus-hpv-associated-cancer-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685904-human-papillomavirus-hpv-associated-cancer-pipeline-review-h2-2016
Key points in table of content
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus (HPV) Associated Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview 10
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis 11
Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12
Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15
Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies 19
Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23
Admedus Ltd 23
Advaxis, Inc. 24
Antigen Express, Inc. 25
Bionor Pharma ASA 26
BioNTech AG 27
Cancer Research Technology Limited 28
Cell Medica Limited 29
Etubics Corporation 30
EyeGene, Inc. 31
Formune S.L. 32
Genexine, Inc. 33
Genticel S.A. 34
iBio, Inc. 35
Immunovaccine, Inc. 36
Inovio Pharmaceuticals, Inc. 37
Inthera Bioscience AG 38
Johnson & Johnson 39
Karyopharm Therapeutics, Inc. 40
Kite Pharma, Inc. 41
MedImmune, LLC 42
Novartis AG 43
Onconova Therapeutics, Inc. 44
Oryx GmbH & Co. KG 45
Profectus BioSciences, Inc. 46
Selecta Biosciences, Inc. 47
Shantha Biotechnics Limited 48
Sirnaomics, Inc. 49
Theravectys SA 50
THEVAX Genetics Vaccine USA Inc 51
Tomegavax, Inc. 52
Transgene SA 53
UbiVac, LLC 54
Vaccibody AS 55
Vault Pharma Inc. 56
Virometix AG 57
ViroStatics srl 58
VLPbio 59
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Target 61
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
ABI-1968 - Drug Profile 69
AEH-10p - Drug Profile 70
alpelisib - Drug Profile 71
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685904
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140083
Google
RSS